OncoLink Cancer Treatment and Resources

Impact of a boost dose of 16 Gy on the local control and cosmesis in patients with early breast cancer: The EORTC boost versus no boost trial



Li Liu, MD
OncoLink Assistant Editor
Last Modified: October 23, 2000

Presenter: H. Bartelink
Affiliation: The Netherlands Cancer Institute


Summary:

Breast conservation therapy (BCT) is a standard of care in the management of patients with early stage breast cancers. BCT results have consistently shown survival equivalence to mastectomy. However, the question remains whether boost is necessary for local tumor control and what its impact is on cosmesis as part of a breast conserving therapy is still unknown. In this study, researchers at the European Organization for Research and Treatment of Cancer (EORTC) reported a phase III randomized trial evaluating the impact of a boost dose of 16 Gy on outcome of patients with early stage breast cancers.


Methods:

  • In this phase III study, a total of 5318 patients with early stage breast cancers who underwent a microscopically complete excision were randomized between no boost or a 16 Gy boost following whole breast irradiation of 50 Gy.
  • Median follow-up was 5.1 years.


Results:

  • For all patients as a whole, younger age (< 40 years) was the single most significant predictor for local recurrence in the multivariate analysis.

  • 5-year actuarial local recurrence rate was 6.8% in the no boost group as compared to 4.3% in the boost group (p<0.0001), favoring the boost group.

  • There was no survival difference between the two groups.

  • Cosmetic results appeared to be better in the no boost group, but the difference was not statistically significant.


Author's Conclusions:

  • 16 Gy boost reduced the local recurrence by 41% (4.3% vs. 6.8%).

  • 16 Gy boost resulted in a slight reduction of cosmetic outcome that was not statistically significant.

  • With a median follow-up of 5.1 years, there was no difference in survival between the boost and the no boost group.

  • Longer follow-up is needed to draw any definitive conclusions.

OncoLink I wish u knew...

Ms. Gambino talks about the complexity of cancer care and the need for patients and families to have help in navigating from diagnosis and treatment decisions to survivorship. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS